Erez Israeli is chief executive officer of Dr. Reddy's Laboratories.

Erez Israeli

Dr. Reddy's Laboratories announced the commercial launch of its generic semaglutide injection in Canada on May 15, 2026,

 making Canada the first G7 country to grant market authorization for a generic semaglutide injection. Dr. Reddy's received a Notice of Compliance from Health Canada on April 28, 2026,

 and launched the product within days of that approval, demonstrating a pre-built commercial and supply chain readiness.

The product is supplied as a sterile solution for subcutaneous injection in a pre-filled pen format, available in a 2 mg/pen and a 4 mg/pen, each delivering semaglutide at a concentration of 1.34 mg/mL. The 2 mg/pen is designed to deliver 0.25 mg or 0.5 mg doses, while the 4 mg/pen delivers 1 mg doses per injection. The once-weekly dosing schedule mirrors the reference product's administration profile, supporting patient familiarity and adherence. Dr. Reddy’s will produce the API, and finished product manufacturing will be done by OneSource Specialty Pharma Limited.

CEO Erez Israeli highlighted the company's expertise in complex drug and peptide development as a key enabler of the launch, as well as its established presence and market access capabilities in Canada. Peptide synthesis at commercial scale involves multi-step synthesis, purification, and formulation processes that require specialized equipment and quality controls.

The approval and launch mark an inflection point for the generic GLP-1 sector. As patent exclusivities on branded semaglutide products continue to be challenged and expire across jurisdictions, manufacturers with established peptide manufacturing platforms, regulatory dossiers, and device manufacturing capabilities will be well-positioned to capture significant market share. Dr. Reddy's early mover advantage in Canada may serve as a regulatory and commercial template for entries into other G7 markets, where demand for affordable GLP-1 therapies continues to intensify amid growing obesity and type 2 diabetes patient populations.

 spoke with Israeli to find out more about Dr. Reddy’s entry into the Canadian GLP-1 market.

PharmTech: How does the collaboration between Dr. Reddy’s API production and OneSource Specialty Pharma Limited’s finished-product manufacturing ensure the high-quality standards required for complex peptide-based therapeutics are met?

 The launch of our generic semaglutide underscores our deep expertise in complex generics and peptide-based therapeutics, built over years of focused investment and innovation. This capability is strengthened by our integrated model, with in-house API manufacturing complemented by robust formulation development capabilities. The API is fully produced within our facilities, while the finished product is currently manufactured in collaboration with our trusted partner, OneSource Specialty Pharma Limited, ensuring both quality and scalability. Also, we are proud to be the first company to receive market authorization for generic semaglutide injection in Canada, marking a significant milestone in our journey. This achievement reflects our ability to meet stringent global regulatory standards and reinforces our commitment to delivering high-quality, affordable therapies. It also strengthens our presence in highly regulated markets, demonstrating our capability to bring complex, innovation-driven products to patients while maintaining the highest standards of quality, safety, and compliance.

With market authorization covering both 2 mg and 4 mg pen delivery systems, what specialized manufacturing capabilities are required to ensure dose accuracy and device reliability?

As GLP-1 is a complex therapy, the dose accuracy and device reliability play an important role. Our generic semaglutide is supplied as a sterile solution for subcutaneous injection in a pre-filled pen, available in 2 mg/pen and 4 mg/pen strengths, each delivering Semaglutide at a concentration of 1.34 mg/ml. The 2 mg/pen is designed to deliver 0.25 mg or 0.5 mg doses, while the 4 mg/pen delivers 1 mg doses per injection. High precision filling ensures each pen delivers the correct drug volume for its intended strength. Each pen is also tested against defined specifications to confirm dose accuracy, device functionality, container closure integrity, and other parameters to ensure dose accuracy and device reliability.

How does the vertical integration of API production help mitigate potential supply chain disruptions for this high-demand GLP-1 therapy?

The launch of the generic semaglutide reflects our decade-long journey in peptide-based therapeutics, supported by strong in-house capabilities in both API manufacturing and formulation development. These therapies are inherently complex, requiring high levels of manufacturing precision, quality control, and regulatory compliance. By integrating both API and formulation development in-house, we are able to maintain greater control across the entire value chain from development through to commercialization, while ensuring a reliable and consistent supply of this important therapy for patients in Canada.

What impact could generic semaglutide have on patient access to GLP-1 therapies?

Generic semaglutide has the potential to significantly enhance access to GLP-1 therapies by improving both accessibility and affordability. More cost-effective options can enable a broader patient population to benefit from these treatments for diabetes management. At Dr. Reddy’s, we believe that introducing high-quality generics can play a key role in expanding access to these important therapies. Our launch of generic semaglutide injection in Canada aligns with our broader commitment to improving access to innovative medicines globally. We also believe that generic semaglutide could play a meaningful role in expanding equitable access to care, contributing to better health outcomes for patients at scale.

Dr. Reddy's Laboratories launches its generic semaglutide injection in Canada. Press release. May 15, 2026. 

https://www.drreddys.com/cms/sites/default/files/2026-05/Semaglutide.pdf

Notice of Compliance Information to Dr Reddys Laboratoris. Health Canada. April 28, 2026. 

https://health-products.canada.ca/noc-ac/nocInfo?no=37419

Dr. Reddy's Laboratories announces Health Canada approval for generic semaglutide injection in Canada. Press release. April 29, 2026. 

https://www.drreddys.com/cms/sites/default/files/2026-04/FinalpressreleaseDrReddysCanadaSemaglutideapproval29042026.pdf

Articles

Dr. Reddy’s launched a generic semaglutide injection in Canada on May 15, 2026, days after receiving Health Canada’s Notice of Compliance, positioning Canada as the first G7 market to authorize a generic semaglutide injection. The once-weekly, prefilled-pen product is offered in 2 mg and 4 mg presentations (1.34 mg/mL) enabling 0.25/0.5 mg and 1 mg dosing, respectively. Dr. Reddy’s supplies the API and partners for finished-product manufacturing, emphasizing precision fill, device testing, and vertical integration to support quality, scalability, and access.

Erez Israeli, chief executive officer of Dr. Reddy's Laboratories, provides insight on the company’s generic version of semaglutide, which entered the Canadian market in May 2026.